Literature DB >> 11257351

Tuberculosis subunit vaccine development: on the role of interferon-gamma.

E M Agger1, P Andersen.   

Abstract

Tuberculosis (TB) remains a major global health problem and subunit vaccines for the control of the disease are presently under development. This vaccine strategy requires an in vitro correlate of protection for the identification of relevant vaccine candidate antigens and for monitoring the induction of a protective cell-mediated immune response after vaccination. New studies of experimental vaccines in the mouse model of TB support interferon-gamma as a relevant marker for the induction of a protective immune response. In contrast, searching for immunodominant antigens capable of inducing strong interferon-gamma responses in PPD positive healthy or TB infected individuals may not identify all relevant candidate antigens for inclusion in a novel TB subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257351     DOI: 10.1016/s0264-410x(00)00519-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.

Authors:  Avi-Hai Hovav; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Identification of pulmonary T-lymphocyte and serum antibody isotype responses associated with protection against Rhodococcus equi.

Authors:  A Marianela Lopez; Melissa T Hines; Guy H Palmer; Debra C Alperin; Stephen A Hines
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

4.  Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation.

Authors:  I S Leal; B Smedegård; P Andersen; R Appelberg
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

5.  Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.

Authors:  Isabel Leroux-Roels; Geert Leroux-Roels; Opokua Ofori-Anyinam; Philippe Moris; Els De Kock; Frédéric Clement; Marie-Claude Dubois; Marguerite Koutsoukos; Marie-Ange Demoitié; Joe Cohen; W Ripley Ballou
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

6.  High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.

Authors:  Sandra Hervas-Stubbs; Laleh Majlessi; Marcela Simsova; Jana Morova; Marie-Jesus Rojas; Clémence Nouzé; Priscille Brodin; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

7.  Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.

Authors:  L Holten-Andersen; T M Doherty; K S Korsholm; P Andersen
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

8.  Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis.

Authors:  Dennis Christensen; Thomas Lindenstrøm; Gijsbert van de Wijdeven; Peter Andersen; Else Marie Agger
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

9.  Reduced frequency of memory T cells and increased Th17 responses in patients with active tuberculosis.

Authors:  Nancy D Marín; Sara C París; Mauricio Rojas; Luis F García
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

10.  Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis.

Authors:  Robert S Wallis; Solange Vinhas; Ernestas Janulionis
Journal:  Tuberculosis (Edinb)       Date:  2009-03-24       Impact factor: 3.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.